GleamWall
中文EN

GERN GERON CORP

Pharmaceutical Preparations · Nasdaq · SEC CIK 886744 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY40.2%
TTM EPS YoY33.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-20.1%
ROA-8.7%
ROIC (approx.)-8.9%
Asset turnover—

Leverage & solvency

Liabilities / assets57.0%
Debt / equity0.53x
Current ratio6.31x
Interest coverage-1.11x

Cash quality & payout

Operating cash flow / net income1.89x
Accruals ratio7.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$60.19M$57.48M$51.84M—$47.23M$49.04M$39.60M—
R&D expense$12.71M$22.03M$14.96M$13.55M$21.07M$21.74M$15.08M$23.43M
SG&A expense$35.70M$38.86M$35.42M$41.67M$39.00M$38.56M$40.02M$43.37M
Operating income$5.80M-$12.50M$158,000-$25.54M-$13.89M-$12.45M-$16.70M-$20.05M
Interest expense$7.21M$7.15M$7.15M$7.30M$8.64M$8.52M$8.20M$8.71M
Net income$1.35M-$16.68M-$3.64M-$28.86M-$18.43M-$16.38M-$19.84M-$25.35M
EBITDA$5.94M-$12.36M$292,000-$25.45M-$13.76M-$12.33M-$16.57M-$19.91M
EPS (basic)0.00-0.02-0.01—-0.03-0.02-0.03—
EPS (diluted)0.00-0.02-0.01—-0.03-0.02-0.03—
Weighted avg. shares (diluted)674.05M670,696669,375—667.10M666,170665,905—
Balance sheet
Cash & equivalents$69.18M$62.64M$68.89M$77.56M$78.12M$77.73M$83.75M$79.02M
Short-term investments———————$327.55M
Receivables$45.98M$51.64M$41.88M$36.99M$35.36M$36.61M$31.17M$35.95M
Inventory$126.60M$123.60M$133.29M$116.64M$95.42M$69.12M$56.22M$38.71M
Current assets$468.74M$486.34M$498.53M$520.27M$522.34M$505.60M$495.77M$490.99M
PP&E, net$1.11M$1.09M$1.00M$884,000$973,000$1.19M$1.15M$1.31M
Total assets$527.11M$519.01M$534.12M$570.54M$567.38M$555.20M$562.45M$593.78M
Current liabilities$74.25M$70.33M$73.57M$111.54M$87.71M$64.28M$63.03M$88.30M
Short-term debt——————$0$0
Long-term debt$120.44M$120.13M$119.83M$119.55M$119.26M$118.99M$118.73M$118.48M
Total debt$120.44M$120.13M$119.83M$119.55M$119.26M$118.99M$118.73M$118.48M
Total liabilities$300.41M$300.39M$305.01M$344.67M$318.68M$295.67M$294.21M$313.46M
Shareholders' equity$226.69M$218.61M$229.11M$225.87M$248.71M$259.53M$268.24M$280.32M
Net debt$51.26M$57.49M$50.94M$41.99M$41.15M$41.26M$34.98M$39.46M
Shares outstanding———639.86M———606.39M
Cash flow statement
Operating cash flow$10.27M-$15.83M-$62.91M-$22.07M-$13.58M-$27.41M-$47.98M-$43.95M
Capital expenditure———————-$141,000
Free cash flow———————-$43.80M
Investing cash flow-$5.91M$8.29M$51.86M$21.14M$13.35M$20.32M$52.44M-$103.51M
Financing cash flow$2.17M$1.38M$2.42M$378,000$542,000$1.09M$256,000$166.16M
Depreciation & amortization$137,000$136,000$134,000$87,000$128,000$128,000$131,000$142,000
Stock-based compensation$4.81M$4.95M$4.91M$5.70M$6.74M$6.74M$7.42M$6.79M

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.